We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
Read MoreHide Full Article
Key Takeaways
CorMedix beat Q1 estimates as DefenCath revenue climbed on stronger dialysis customer demand.
CRMD raised 2026 revenue outlook to $325M-$345M after stronger-than-expected Q1 results.
CorMedix posted higher EBITDA and advanced Rezzayo and taurolidine/heparin studies.
CorMedix Therapeutics (CRMD - Free Report) delivered first-quarter 2026 diluted earnings of 43 cents per share, up 43.3% year over year, beating the Zacks Consensus Estimate of 35 cents.
Net revenue was $127.4 million, up significantly from the year-ago sales of $39.08 billion. The reported figure beat the Zacks Consensus Estimate of $110 million.
Results reflected stronger DefenCath execution and underlying demand trends, with DefenCath net revenues of $97.5 million in the quarter.
Management also lifted its full-year outlook following the better-than-expected start to 2026. The stock gained 5.7% on Thursday following the earnings release.
CRMD's DefenCath Uptake Anchors the Quarter
DefenCath remained the key operating lever in the period, supported by higher utilization among outpatient dialysis customers. Its sales increased, primarily boosted by the onboarding of a large dialysis organization in mid-2025, along with strong positive demand trends.
Quarterly DefenCath performance also benefited from a favorable change in estimate tied to certain sales allowances, including items such as Medicaid rebates and product returns. While that impact provided a lift, management pointed to underlying utilization momentum as the more important signal on demand durability.
CRMD’s Melinda Portfolio Contributes to the Topline
The Melinta portfolio contributed $29.9 million in the first quarter. Its acquisition in the last year added a meaningful second revenue stream and broadened CorMedix’s commercial footprint.
The Melinta contribution also changed the year-over-year comparison framework for CorMedix, given that the acquisition occurred in August 2025. As a result, the year-ago period reflected revenue from only DefenCath, making the current quarter’s mix and scale structurally different.
Shares of CorMedix have plunged 31.9% so far this year against the industry’s 1.1% growth.
Image Source: Zacks Investment Research
CRMD's Costs Rise With Integration and Pipeline Spend
Operating expenses increased sharply year over year as the company absorbed a larger cost base following the Melinta acquisition. Total operating expenses were $41.5 million, up 138.5% from the prior-year quarter, which management attributed primarily to expenses related to the acquired portfolio and the broader combined-company footprint.
R&D expenses climbed to $7.2 million, up 125% year over year, due to higher personnel spending and clinical trial services tied to ongoing programs, including pediatric studies for certain brands and continued DefenCath development work. Commercial and corporate costs also rose with scale, as selling and marketing expenses increased significantly to $12.5 million and general and administrative expenses rose abruptly to $21.7 million, reflecting the expanded portfolio and related operating requirements.
CorMedix Lifts 2026 Guidance After Strong Start
Management raised its full-year 2026 net revenue outlook to the range of $325-$345 million from $300-$320 million, citing strong first-quarter execution and continued confidence in underlying demand. The revised range represents an increase from CRMD’s previously established revenue expectations.
CorMedix also increased full-year adjusted EBITDA guidance to a range of $115-$135 million from $100-$125 million. The updated profitability view suggests management expects operating leverage to continue as the company integrates the broader product set and sustains DefenCath utilization growth.
CRMD's Key Pipeline Updates
CorMedix highlighted progress across its late-stage pipeline in the first-quarter earnings release. Last month, the company announced positive phase III top-line results from the global ReSPECT clinical study evaluating Rezzayo (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation. CorMedix said it is working with its global partner to prepare a supplemental new drug application expected to be submitted in the second half of this year, with a potential commercial launch for the expanded indication in 2027.
CorMedix also provided an update on its ongoing phase III study of taurolidine/heparin catheter lock solution in total parenteral nutritionpatients, which continues to enroll and is currently trending to completion in 2028. Management noted it is taking steps to accelerate enrollment, including opening new study sites and submitting a protocol amendment to the FDA that, if approved, would remove certain exclusion criteria and broaden patient enrollment.
Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have also narrowed from $5.50 to $4.64. AMRN shares have risen 5.9% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 50.02%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV shares have risen 5.4% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. On the other hand, its 2026 EPS is currently pegged at 11 cents. IMCR shares have lost 17.2% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
Key Takeaways
CorMedix Therapeutics (CRMD - Free Report) delivered first-quarter 2026 diluted earnings of 43 cents per share, up 43.3% year over year, beating the Zacks Consensus Estimate of 35 cents.
Net revenue was $127.4 million, up significantly from the year-ago sales of $39.08 billion. The reported figure beat the Zacks Consensus Estimate of $110 million.
Results reflected stronger DefenCath execution and underlying demand trends, with DefenCath net revenues of $97.5 million in the quarter.
Management also lifted its full-year outlook following the better-than-expected start to 2026. The stock gained 5.7% on Thursday following the earnings release.
CRMD's DefenCath Uptake Anchors the Quarter
DefenCath remained the key operating lever in the period, supported by higher utilization among outpatient dialysis customers. Its sales increased, primarily boosted by the onboarding of a large dialysis organization in mid-2025, along with strong positive demand trends.
Quarterly DefenCath performance also benefited from a favorable change in estimate tied to certain sales allowances, including items such as Medicaid rebates and product returns. While that impact provided a lift, management pointed to underlying utilization momentum as the more important signal on demand durability.
CRMD’s Melinda Portfolio Contributes to the Topline
The Melinta portfolio contributed $29.9 million in the first quarter. Its acquisition in the last year added a meaningful second revenue stream and broadened CorMedix’s commercial footprint.
The Melinta contribution also changed the year-over-year comparison framework for CorMedix, given that the acquisition occurred in August 2025. As a result, the year-ago period reflected revenue from only DefenCath, making the current quarter’s mix and scale structurally different.
Shares of CorMedix have plunged 31.9% so far this year against the industry’s 1.1% growth.
Image Source: Zacks Investment Research
CRMD's Costs Rise With Integration and Pipeline Spend
Operating expenses increased sharply year over year as the company absorbed a larger cost base following the Melinta acquisition. Total operating expenses were $41.5 million, up 138.5% from the prior-year quarter, which management attributed primarily to expenses related to the acquired portfolio and the broader combined-company footprint.
R&D expenses climbed to $7.2 million, up 125% year over year, due to higher personnel spending and clinical trial services tied to ongoing programs, including pediatric studies for certain brands and continued DefenCath development work. Commercial and corporate costs also rose with scale, as selling and marketing expenses increased significantly to $12.5 million and general and administrative expenses rose abruptly to $21.7 million, reflecting the expanded portfolio and related operating requirements.
CorMedix Lifts 2026 Guidance After Strong Start
Management raised its full-year 2026 net revenue outlook to the range of $325-$345 million from $300-$320 million, citing strong first-quarter execution and continued confidence in underlying demand. The revised range represents an increase from CRMD’s previously established revenue expectations.
CorMedix also increased full-year adjusted EBITDA guidance to a range of $115-$135 million from $100-$125 million. The updated profitability view suggests management expects operating leverage to continue as the company integrates the broader product set and sustains DefenCath utilization growth.
CRMD's Key Pipeline Updates
CorMedix highlighted progress across its late-stage pipeline in the first-quarter earnings release. Last month, the company announced positive phase III top-line results from the global ReSPECT clinical study evaluating Rezzayo (rezafungin for injection) for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation. CorMedix said it is working with its global partner to prepare a supplemental new drug application expected to be submitted in the second half of this year, with a potential commercial launch for the expanded indication in 2027.
CorMedix also provided an update on its ongoing phase III study of taurolidine/heparin catheter lock solution in total parenteral nutritionpatients, which continues to enroll and is currently trending to completion in 2028. Management noted it is taking steps to accelerate enrollment, including opening new study sites and submitting a protocol amendment to the FDA that, if approved, would remove certain exclusion criteria and broaden patient enrollment.
CorMedix Inc Price, Consensus and EPS Surprise
CorMedix Inc price-consensus-eps-surprise-chart | CorMedix Inc Quote
CRMD’s Zacks Rank & Stocks to Consider
CorMedix currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Amarin Corporation (AMRN - Free Report) , Indivior Pharmaceuticals (INDV - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have also narrowed from $5.50 to $4.64. AMRN shares have risen 5.9% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 50.02%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV shares have risen 5.4% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Immunocore’s 2026 loss per share have narrowed from 97 cents to 16 cents. On the other hand, its 2026 EPS is currently pegged at 11 cents. IMCR shares have lost 17.2% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.